EULAV Asset Management’s Integra LifeSciences IART Stock Holding History

EULAV Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13,400	Closed	-$604K	–	309
2018 Q4	$604K	Sell	13,400 -2,500	-16%	-$137K	0.03%	260
2018 Q3	$1.05M	Hold	15,900	–	–	0.04%	242
2018 Q2	$1.02M	Hold	15,900	–	–	0.05%	234
2018 Q1	$880K	Buy	+15,900	New	+$833K	0.04%	234

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EULAV Asset Management's IART Position: Q1 2019 in Review

EULAV Asset Management sold out of Integra LifeSciences (IART) in Q1 2019, closing a stake of 13,400 shares — an estimated $604K sold.

EULAV Asset Management first reported a position in IART in Q1 2018 and held it in 4 quarters. The position peaked at $1.05M in Q3 2018. 259 funds tracked by Wall St. Rank hold IART as of Q1 2019.

EULAV Asset Management reported no remaining Integra LifeSciences position as of Q1 2019 after selling out during the quarter.
EULAV Asset Management sold 13,400 Integra LifeSciences shares in Q1 2019, an estimated $604K.
EULAV Asset Management first reported a position in Integra LifeSciences in Q1 2018 and held it in 4 quarters.
EULAV Asset Management's Integra LifeSciences position peaked at $1.05M in Q3 2018.
259 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2019.

Based on EULAV Asset Management's 13F filing for Q1 2019, filed 13 May 2019.